Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18512868 | 1.00 | ADORA2A (0.54) | ADORA2AADORA2BCYP1A2MEN1KMT2A | |
| SCHEMBL20580087 | 1.00 | ADORA2A (0.54) | ADORA2AADORA2BCYP1A2MEN1KMT2A | |
| SCHEMBL18512927 | 1.00 | ADORA2A (0.54) | ADORA2AADORA2BCYP1A2MEN1KMT2A | |
| SCHEMBL14917346 | 1.00 | ADORA2A (0.54) | ADORA2AADORA2BCYP1A2MEN1KMT2A | |
| SCHEMBL29388193 | 0.99 | ADORA2A (0.53) | ADORA2AADORA2BCYP1A2MEN1KMT2A | |
| SCHEMBL19645975 | 0.93 | ADORA2A (0.53) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL62505 | 0.89 | CYP2C19 (0.62) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL343478 | 0.89 | CYP2C19 (0.62) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL14931005 | 0.89 | CYP2C19 (0.62) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 | |
| SCHEMBL18512921 | 0.89 | CYP2C19 (0.62) | ADORA2AADORA2BCYP1A2ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2031 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119173636-A | RNA molecules | 帝国理工学院创新有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240279676-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-11072808-B2 | Methods and compositions for increasing capping efficiency of transcribed RNA | NEW ENGLAND BIOLABS, INC. (US) | 2021-07-27 | — | — | US | claimed |
| US-20210108252-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | claimed |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | Arcturus, Inc. (US) | 2021-04-06 | — | — | US | claimed |
| EP-3656872-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2020-05-27 | — | — | EP | claimed |
| US-20200109425-A1 | Methods and Compositions for Increasing Capping Efficiency of Transcribed RNA | NEW ENGLAND BIOLABS, INC. (US) | 2020-04-09 | — | — | US | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| US-20180105551-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. | 2018-04-19 | — | — | US | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |